Category Respiratory Infections (non-tuberculous) **Presentation type** Oral

OVERCOMING BIOFILM MEDIATED RESPIRATORY INFECTIONS THROUGH EXPLOITATION OF PATHOGEN AND HOST-DIRECTED NOVEL PEPTIDES.

Dhammika Leshan Wannigama^{1*}, Cameron Hurst², Peter Monk³, Anthony Kicic⁴, Stephen Stick⁴, and Tanittha Chatsuwan⁵


¹Department of Microbiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thailand, and School of Medicine, Faculty of Health and Medical Sciences, The University of Western Australia, Nedlands, Western Australia, Australia. ²QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia., Australia, ³Department of Infection, Immunity & Cardiovascular Disease University of Sheffield Medical School, United Kingdom, ⁴Division of Pediatrics, School of Medicine, Faculty of Health and Medical Sciences, The University of Western Australia, Nedlands, Western Australia, Australia and Telethon Kids Institute, Centre for Health Research, The University of Western Australia, Nedlands, Western Australia, Australia, and ⁵Department of Microbiology, Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Bangkok, Thailand., Thailand


Background and Aims: The recurrent and chronic *P. aeruginosa,* biofilm colonization on the respiratory tract is the most prevalent cause of morbidity and mortality in patients with ventilator-associated pneumonia, cystic fibrosis (CF), chronic asthma and lung cancer. This situation has generated an urgent need for development of innovative, efficient and targeted treatments. Interest in host defence peptides (HDPs) has grown due to their potential therapeutic applications and their possible use against biofilm. This study, short, synthetic cationic peptides were tested for their anti-biofilm effectiveness as well as their ability to inhibit and disperse the ability of *P. aeruginosa* biofilms.

Methods: The clinical isolates of *P. aeruginosa* from patients with chronic lung infections were used as a model to investigate inhibit and disperse of bacterial biofilms by synthetic short sequence defence peptides (HDPs).

Results: The number of different novel anti-biofilm peptide candidates was tested against P. aeruginosa, and was found to exhibit an anti-microbial, anti-attachment as well as anti-biofilm activity at concentrations in the low $\mu g/ml$ range compare with current conventional antibiotics. Confocal laser scanning microscopy and CFU count revealed that peptide treatment inhibited biofilm formation resulting in bio-volume reduction followed by induced disruption of mature biofilms and other chronic virulent factors. Further, peptides significantly reduce the extracellular matrix substance of mature biofilms.

Conclusion: These findings highlight the potential of novel peptides as a new group of antimicrobial weapons for disrupt biofilms and suggesting its potential use as a model for designing new treatment for chronic lung infections.





Time laps effect of PEP-FOLD_Q17752281929970 peptide on mature biofilm MBEC $\leq 8 \mu$ M/ml (Minimal Biofilm eradication concentrations (MBEC) analyzed with high resolution confocal lase scan microscopy